May 9, 2013
Astellas Pharma announced on May 7 that the company signed a license agreement with Drais Pharmaceuticals of the US to develop and commercialize ASP7035, a vasopressin V 2 receptor selective agonist discovered by Astellas to treat nocturia. This is the...read more